NRG Oncology CC001 Neurocognitive Final Analysis: A Phase III Trial of Hippocampal Avoidance (HA) in Addition to Whole-Brain Radiotherapy (WBRT) Plus Memantine to Preserve Neurocognitive Function (NCF) in PatientsWith Brain Metastases (BM) Conference

Wefel, Jeffrey S, Pugh, Stephanie, Gondi, Vinai et al. (2019). NRG Oncology CC001 Neurocognitive Final Analysis: A Phase III Trial of Hippocampal Avoidance (HA) in Addition to Whole-Brain Radiotherapy (WBRT) Plus Memantine to Preserve Neurocognitive Function (NCF) in PatientsWith Brain Metastases (BM) . NEUROSURGERY, 66 137-138.

cited authors

  • Wefel, Jeffrey S; Pugh, Stephanie; Gondi, Vinai; Brown, Paul D; Tome, Wolfgang; Armstrong, Terri S; Bruner, Deborah; Bovi, Joseph; Robinson, Cliff; Khuntia, Deepak; Grosshans, David; Konski, Andre; Roberge, David; Kundapur, Vijayananda; Devisetty, Kiran; Shah, Sunjay; Usuki, Kenneth; Anderson, Bethany; Mehta, Minesh P; Kachnic, Lisa

authors

date/time interval

  • October 19, 2019 -

publication date

  • September 1, 2019

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Science & Technology
  • Surgery

Location

  • CA, San Francisco

Conference

  • Annual Meeting of the Congress-of-Neurological-Surgeons

publisher

  • OXFORD UNIV PRESS INC

start page

  • 137

end page

  • 138

volume

  • 66